Michigan Medicine, Frankel Cardiovascular Center, United States; Michigan Medicine, Institute for Healthcare Policy and Innovation, United States.
Michigan Medicine, Institute for Healthcare Policy and Innovation, United States.
Prog Cardiovasc Dis. 2018 Mar-Apr;60(6):600-606. doi: 10.1016/j.pcad.2018.03.002. Epub 2018 Mar 10.
Peri-procedural management of oral anticoagulants can be complex and confusing for many providers. It involves a careful balance of a patient's thromboembolic risk and bleeding risk. For every patient chronically taking an oral anticoagulant who will be undergoing an elective procedure, a four step approach may be considered when creating a plan for the oral anticoagulant. (1) Does the oral anticoagulant need to stop for the procedure? (2) If yes, when should the oral anticoagulant be stopped pre-procedure? (3) Does the patient require a "bridging" parenteral anticoagulant? (4) When should anticoagulation be re-started post procedure? Based on the unique features of warfarin versus the direct oral anticoagulants (DOAC), a unique, personalized plan should be developed and tailored to the individual patient. Anticoagulant specialists, such as anticoagulation clinic pharmacists, may help facilitate this process.
围手术期管理口服抗凝剂对许多医生来说可能是复杂和令人困惑的。它涉及到患者血栓栓塞风险和出血风险之间的谨慎平衡。对于每个长期服用口服抗凝剂并将接受择期手术的患者,在制定口服抗凝剂计划时,可以考虑采用四步方法。(1)该口服抗凝剂是否需要因该手术而停药?(2)如果是,应该在术前何时停药?(3)患者是否需要“桥接”的肠外抗凝剂?(4)术后何时应重新开始抗凝?基于华法林与直接口服抗凝剂(DOAC)的独特特征,应制定一个独特的、个性化的计划,并针对个体患者进行调整。抗凝专家,如抗凝门诊药师,可能有助于促进这一过程。